Graft-versus-host disease screening: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Screening of the general population for GvHD is not recommended. | |||
==Screening== | |||
Screening of the general population for GvHD is not recommended. This is because GvHD can only occur in persons who undergo stem cell transplant, and only a very small fraction of persons will undergo stem cell transplant. The cost of screening to identify persons at risk would outweigh the benefits. | |||
==References== | ==References== | ||
| Line 11: | Line 13: | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
Latest revision as of 00:03, 5 July 2017
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease screening On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease screening |
|
Risk calculators and risk factors for Graft-versus-host disease screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Screening of the general population for GvHD is not recommended.
Screening
Screening of the general population for GvHD is not recommended. This is because GvHD can only occur in persons who undergo stem cell transplant, and only a very small fraction of persons will undergo stem cell transplant. The cost of screening to identify persons at risk would outweigh the benefits.